公开(公告)号：US20240174614A1

公开(公告)日：2024-05-30

申请号：US18341613

申请日：2023-06-26

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John E. Dowling ,  John Clifford Chabala

IPC: C07D215/38 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D261/06 ,  C07D275/00 ,  C07D277/40 ,  C07D277/56 ,  C07D333/04

CPC classification number: C07D215/38 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D261/06 ,  C07D275/00 ,  C07D277/40 ,  C07D277/56 ,  C07D333/04

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

公开(公告)号：US11724987B2

公开(公告)日：2023-08-15

申请号：US17164556

申请日：2021-02-01

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John E. Dowling ,  John Clifford Chabala

IPC: A61K31/4418 ,  A61K31/41 ,  A61K31/423 ,  C07D215/38 ,  A61K31/44 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/60 ,  C07D277/40 ,  C07D277/56 ,  C07D261/06 ,  C07D275/00 ,  C07D333/04 ,  C07C229/56 ,  A61K31/47

CPC classification number: C07D215/38 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D261/06 ,  C07D275/00 ,  C07D277/40 ,  C07D277/56 ,  C07D333/04

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

公开(公告)号：US09265759B2

公开(公告)日：2016-02-23

申请号：US14581462

申请日：2014-12-23

Applicant: ALDEYRA THERAPEUTICS, INC.

Inventor： Thomas A. Jordan ,  John E. Dowling ,  John Clifford Chabala

IPC: A61K31/47 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D215/38 ,  C07D277/40 ,  C07D277/56

CPC classification number: C07D215/38 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D277/40 ,  C07D277/56

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

公开(公告)号：US10913722B2

公开(公告)日：2021-02-09

申请号：US16241851

申请日：2019-01-07

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John E. Dowling ,  John Clifford Chabala

IPC: C07D261/06 ,  C07D275/00 ,  C07D333/04 ,  C07D215/38 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/60 ,  C07D277/40 ,  C07D277/56 ,  C07C229/56 ,  A61K31/47

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

公开(公告)号：US09896419B2

公开(公告)日：2018-02-20

申请号：US15488205

申请日：2017-04-14

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John E. Dowling ,  John Clifford Chabala

IPC: A61K31/47 ,  C07D215/38 ,  C07D277/56 ,  C07D277/40 ,  C07C229/60 ,  C07C229/56 ,  A61K31/44 ,  A61K31/4706 ,  A61K31/435 ,  A61K31/426 ,  A61K31/423 ,  A61K31/41 ,  A61K31/4418 ,  C07C215/68

CPC classification number: C07D215/38 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/47 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/56 ,  C07C229/60 ,  C07D277/40 ,  C07D277/56

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

公开(公告)号：US12097188B2

公开(公告)日：2024-09-24

申请号：US18241598

申请日：2023-09-01

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John Clifford Chabala ,  Gerald D. Cagle

IPC: A61K31/423 ,  A61K9/00 ,  A61K31/47 ,  A61K47/40

CPC classification number: A61K31/423 ,  A61K9/0048 ,  A61K31/47 ,  A61K47/40

Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

公开(公告)号：US20230041335A1

公开(公告)日：2023-02-09

申请号：US17929273

申请日：2022-09-01

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. JORDAN ,  John E. Dowling ,  John Clifford Chabala

IPC: C07D215/38 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/41 ,  A61K31/423 ,  A61K31/426 ,  A61K31/435 ,  A61K31/4706 ,  C07C215/68 ,  C07C229/60 ,  C07D277/40 ,  C07D277/56 ,  C07D261/06 ,  C07D275/00 ,  C07D333/04 ,  C07C229/56 ,  A61K31/47

Abstract: Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

公开(公告)号：US10111862B2

公开(公告)日：2018-10-30

申请号：US14760041

申请日：2014-01-21

Applicant: Aldeyra Therapeutics, Inc.

Inventor： John Clifford Chabala ,  Thomas A. Jordan ,  Ke-Qing Ling ,  John G. Gleason ,  William A. Kinney

IPC: C07D261/20 ,  C07D263/57 ,  A61K31/421

Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.

公开(公告)号：US20180092882A1

公开(公告)日：2018-04-05

申请号：US15782470

申请日：2017-10-12

Applicant: Aldeyra Therapeutics, Inc.

Inventor： Thomas A. Jordan ,  John Clifford Chabala ,  Gerald D. Cagle

IPC: A61K31/423 ,  A61K31/47 ,  A61K47/40 ,  A61K9/00

CPC classification number: A61K31/423 ,  A61K9/0048 ,  A61K31/47 ,  A61K47/40

Abstract: The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

公开(公告)号：US20190125729A1

公开(公告)日：2019-05-02

申请号：US16168309

申请日：2018-10-23

Applicant: Aldeyra Therapeutics, Inc.

Inventor： John Clifford Chabala ,  Thomas A. Jordan ,  Ke-Qing Ling ,  John G. Gleason ,  William A. Kinney

IPC: A61K31/421 ,  C07D263/57 ,  C07D261/20

Abstract: The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.